

Dapagliflozin Oral Solution (a 505B2 NDA Product)

Shashikanth Varala
Mobile: (+44)7505457665
Email: shashi@mahashiv.co.uk
Mahashiv Limited
Unit 1, Kataria Point, 1 Riches Road,
Illford, England, IG1 1JH

Rob Camerer
Mobile: (417) 770-4600
Tel: (417) 885-7000
Email: robcamerer@globalpharmapartners.com

Timelines for Developing Brand XXXXXX ®

- Definitive Agreement – Q3 2023
- Completion of 3×3 exhibit (pivotal) batches of drug product: Q1 2024
- 6 Month stability completion: Q3 2024
- BE study completion: Q2 2024
- Estimated FDA filing date: Q1 2025
- FDA approval: Q1 2026

Terms for US Partner:

- Total Milestone payments: \$800,000
 - \$200,000 on signing
 - \$200,000 on Bioequivalence study Acceptance
 - \$200,000 on 505(b)(2) filing to FDA
 - \$200,000 on FDA Approval
- Filing Fee: Partner pays upfront (recoup 50% of fee from profits)
- Profit sharing: DP 50%/ 50% Partner
- Length of Term: 10 years

Estimated Remaining Development Costs (50% DP/50% Partner):

- Formulation Development Cost: \$500,000
- Submission batches: \$ 250,000 (India) (5 batches- 3 validation and two feasibility batches; includes API cost of \$3000)
- Bioequivalence studies: \$300,000
- Stability & non-clinical studies: *\$100,000

+ Please note that the submission batches costs from India, should we move to EU/US CDMO, then costs will increase.

Estimated Commercial Finished Dose Cost

COG: \$12.00 per unit-dose bottle pack (150ml) includes packaging, shipping, insurance etc. Please note that these COGS are based on manufacturing in India, should we move manufacturing to EU/US CDMO, then costs will increase.

RLD PRODUCT NAME

Farxiga ® Tablet, 5mg, 10mg

API NAME

Dapagliflozin Propanediol Monohydrate

DOSAGE FORM

Oral Solution, 10mg/5ml

INDICATION

Type 2 diabetes

PATENT STATUS

Mahashiv owns Patent Pending for the product and technology

PARAGRAPH IV CERTIFICATION

NA

ANDA FILER

NA

POTENTIAL COMPETITORS

No generic competition

EARLIEST GENERIC LAUNCH

NA